Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
Aastrom Biosciences Raises $10 Million in Equity Financing Ann Arbor, Michigan, October 27, 2004 - Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has executed definitive Stock Purchase Agreements for the sale of approximately 8.26 million shares of the Company's common stock in
ANN ARBOR, Mich., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that its previously announced one-for-twenty reverse
-- The Following is a Statement from R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom Biosciences, Inc. Regarding Recent Article in New Scientist Magazine --
ANN ARBOR, Mich., Feb 22, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the Company intends to seek shareholder approval to authorize the Board of Directors to amend Aastrom's Restated Articles
Aastrom Biosciences Holds Investor Conference Call Today Ann Arbor, Michigan, November 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) will hold an investor call today, November 14, 2003 at 10:00 a.m. EST. The purpose of the call is to bring shareholders and other interested parties
ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter
